CN115968368A - 喹诺酮化合物及其制备方法 - Google Patents
喹诺酮化合物及其制备方法 Download PDFInfo
- Publication number
- CN115968368A CN115968368A CN202180050996.5A CN202180050996A CN115968368A CN 115968368 A CN115968368 A CN 115968368A CN 202180050996 A CN202180050996 A CN 202180050996A CN 115968368 A CN115968368 A CN 115968368A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- pseudomonadin
- alkyl
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Quinolone compound Chemical class 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 229960004555 rutoside Drugs 0.000 claims abstract description 20
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 22
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 17
- 229910021529 ammonia Inorganic materials 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 13
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 13
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 13
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 13
- 235000005493 rutin Nutrition 0.000 claims description 13
- 230000000996 additive effect Effects 0.000 claims description 12
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- 239000001099 ammonium carbonate Substances 0.000 claims description 9
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- IOAJXKLCPQGUJX-UHFFFAOYSA-N 8-methoxy-2-methyl-5-octyl-1H-quinolin-4-one Chemical compound COC=1C=CC(=C2C(C=C(NC=12)C)=O)CCCCCCCC IOAJXKLCPQGUJX-UHFFFAOYSA-N 0.000 claims description 8
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical group I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910001507 metal halide Inorganic materials 0.000 claims description 7
- 150000005309 metal halides Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005580 one pot reaction Methods 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 claims description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 235000011181 potassium carbonates Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 abstract description 30
- 150000001412 amines Chemical class 0.000 abstract description 7
- 229930014626 natural product Natural products 0.000 abstract description 7
- 238000006257 total synthesis reaction Methods 0.000 abstract description 7
- 125000003118 aryl group Chemical group 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000004896 high resolution mass spectrometry Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000003039 volatile agent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- COBBNRKBTCBWQP-UHFFFAOYSA-N Graveoline Chemical compound C1=C2OCOC2=CC(C=2N(C3=CC=CC=C3C(=O)C=2)C)=C1 COBBNRKBTCBWQP-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- UYRHHBXYXSYGHA-UHFFFAOYSA-N 2-heptyl-4-quinolone Chemical compound C1=CC=C2NC(CCCCCCC)=CC(=O)C2=C1 UYRHHBXYXSYGHA-UHFFFAOYSA-N 0.000 description 4
- JGABMVVOXLQCKZ-UHFFFAOYSA-N 2-phenyl-1h-quinolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=CC=1C1=CC=CC=C1 JGABMVVOXLQCKZ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- ZCPBFVVRNKXFEN-UHFFFAOYSA-N 5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)C=CCC2=C1 ZCPBFVVRNKXFEN-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- DDWQZZRJKTVNGX-UHFFFAOYSA-N 2-(4-fluorophenyl)-1h-quinolin-4-one Chemical compound C1=CC(F)=CC=C1C1=CC(=O)C2=CC=CC=C2N1 DDWQZZRJKTVNGX-UHFFFAOYSA-N 0.000 description 2
- VCANFRORCMQOFD-UHFFFAOYSA-N 2-butyl-1h-quinolin-4-one Chemical compound C1=CC=C2NC(CCCC)=CC(=O)C2=C1 VCANFRORCMQOFD-UHFFFAOYSA-N 0.000 description 2
- RNOILIZGNHABIB-UHFFFAOYSA-N 2-cyclopropyl-1h-quinolin-4-one Chemical compound N1C2=CC=CC=C2C(=O)C=C1C1CC1 RNOILIZGNHABIB-UHFFFAOYSA-N 0.000 description 2
- MZWURLAWTNWBGV-UHFFFAOYSA-N 2-dodecyl-1h-quinolin-4-one Chemical compound C1=CC=C2NC(CCCCCCCCCCCC)=CC(=O)C2=C1 MZWURLAWTNWBGV-UHFFFAOYSA-N 0.000 description 2
- YODYNZHLZUOZLK-UHFFFAOYSA-N 2-octyl-1h-quinolin-4-one Chemical compound C1=CC=C2NC(CCCCCCCC)=CC(=O)C2=C1 YODYNZHLZUOZLK-UHFFFAOYSA-N 0.000 description 2
- IPVMHKHKTQYJIL-UHFFFAOYSA-N 2-phenyl-1h-1,8-naphthyridin-4-one Chemical compound N1C2=NC=CC=C2C(=O)C=C1C1=CC=CC=C1 IPVMHKHKTQYJIL-UHFFFAOYSA-N 0.000 description 2
- GRZYIWNQLYTMIF-UHFFFAOYSA-N 3-bromo-8-methoxy-2-methyl-5-octyl-1H-quinolin-4-one Chemical compound BrC1=C(NC2=C(C=CC(=C2C1=O)CCCCCCCC)OC)C GRZYIWNQLYTMIF-UHFFFAOYSA-N 0.000 description 2
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical group C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012966 insertion method Methods 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- QBNOPZJAURRQCE-UHFFFAOYSA-M magnesium;prop-1-yne;bromide Chemical compound [Mg+2].[Br-].CC#[C-] QBNOPZJAURRQCE-UHFFFAOYSA-M 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- IOKWXGMNRWVQHX-VAWYXSNFSA-N (e)-1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)-3-phenylprop-2-en-1-one Chemical compound O=[N+]1C2=CC=CC=C2N([O-])C(C)=C1C(=O)\C=C\C1=CC=CC=C1 IOKWXGMNRWVQHX-VAWYXSNFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XGXUGXPKRBQINS-UHFFFAOYSA-N 2,4-dibromo-1-methoxybenzene Chemical compound COC1=CC=C(Br)C=C1Br XGXUGXPKRBQINS-UHFFFAOYSA-N 0.000 description 1
- DXKBEYOQZCDHHK-UHFFFAOYSA-N 2,6-dibromo-3-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C(C=O)=C1Br DXKBEYOQZCDHHK-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- YXHVKMDHNXFOQN-UHFFFAOYSA-N 2-cyclohexyl-1h-quinolin-4-one Chemical compound N1C2=CC=CC=C2C(=O)C=C1C1CCCCC1 YXHVKMDHNXFOQN-UHFFFAOYSA-N 0.000 description 1
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 1
- NWINIEGDLHHNLH-UHFFFAOYSA-N 2-methyl-1h-quinolin-4-one Chemical compound C1=CC=CC2=NC(C)=CC(O)=C21 NWINIEGDLHHNLH-UHFFFAOYSA-N 0.000 description 1
- OYIJPSOHAVBTPC-UHFFFAOYSA-N 5-bromo-2-phenyl-1H-quinolin-4-one Chemical compound O=C1C(C(Br)=CC=C2)=C2NC(C2=CC=CC=C2)=C1 OYIJPSOHAVBTPC-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 238000010763 Camps quinoline synthesis reaction Methods 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000005966 aza-Michael addition reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- GKFRVXOKPXCXAK-UHFFFAOYSA-N octylboronic acid Chemical compound CCCCCCCCB(O)O GKFRVXOKPXCXAK-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 150000003305 rutin Chemical class 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
技术领域
本发明涉及式(I)的喹诺酮和类似物;以及通过将胺***到其芳基炔酮中来制备它的方法。
其中,X=C、N、C-OMe;R1=H、CH3;R2=C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基、3,4-亚甲基二氧苯基;R3=H、OMe;R4=H、C1-C8烷基、溴;R5=H;R6=H;R5和R6能够结合在一起形成-OCH2O-。
本发明还涉及作为具有通式(I)的喹诺酮的芸香碱(graveoline)(1)、芸香宁碱(graveolinine)(2)、假单素(pseudane)IV(3)、假单素VII(4)、假单素VIII(5)、假单素XII(6)和和他草喹诺酮(waltherione)F(7)的制备方法。
具体地,本发明还涉及具有通式I的芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)、假单素XII(6)和和他草喹诺酮F(7)的全合成。
背景技术
本申请中的方案聚焦于称为喹诺酮的双环含氮杂环化合物的合成。喹诺酮及其衍生物因其广泛存在于多种天然产物和药物中且表现出广泛的生物特性,已经引起了显著的关注(J.Med.Chem.2014,57,1952,Chem.Rev.2011,111,152)。4-喹诺酮环是存在于多种生物碱中的常见基序,并且是显示重要药物活性的药物中的重要基序,因此被认为是药物的优选构建单元。喹诺酮及其衍生物作为不同治疗剂的重要性在以下方面有很好的先例:抗肿瘤剂(US2005/0032832,WO 96/10563),抗有丝***剂(WO02/26730,Eur.J.Med.Chem.2011,46,6046),抗疟疾剂(J.Med.Chem.2014,57,3818),抗病毒剂,黄嘌呤氧化酶和组织蛋白酶抑制活性(Arch.Pharm.2013,346,7),自诱导物(WO 02/18342),C-MYC/MAX/DNA复合物形成的抑制剂(WO 2018/021810 A1),抗细菌或抗真菌剂,锌传感器(WO2017/017631A2,WO 2017/220205 A1),赖氨酰氧化酶样2(LOXL2)抑制剂(WO 2017/139274A1),治疗顶复门寄生虫相关病症(WO2017/112678 A1),酪氨酸酶和相关蛋白的活性抑制剂(WO 2017/181379 A1),作为变构调节剂用于治疗诸如阿尔茨海默病、精神***症疼痛或睡眠障碍等疾病(WO 2017/160670 A1),在铜绿假单胞菌的细胞间通讯***中充当细胞间信号分子的自诱导物(WO 02/18342 A2)等。
合成4-喹啉酮的经典方法包括Lappin环化(J.Am.Chem.Soc.1948,70,3348),涅门托夫斯基法(Tetrahedron Lett.2002,43,3911),Conrad-Limpet法(Eur.J.Org.Chem.2010,2010,5841),Camps环化(Chem.Ber.1899,32,3228,Org.Lett.2008,10,2609)和Grohe-Heitzer合成(Liebigs Ann.Chem.1987,1987,29)。在许多合成中,包括多步骤方法来构建烯胺酮前体,并且还需要高温以进行环化。Camps法是将苯胺与麦氏酸(或其衍生物)和原甲酸三甲酯缩合以得到相应的烯胺,然后将烯胺在高沸点溶剂中环化(Synthesis 1987,482)或在微波条件下环化(Bioorg.Med.Chem.Lett.2005,15,1015),以实现环化并产生喹诺酮。除上述之外,还有其他一些关于使用过渡金属催化剂合成喹诺酮的报道(J.Org.Chem.2007,72,7968,Eur.J.Org.Chem.2012,3001,Eur.J.Org.Chem.2014,4044)。在合成中,很少有方法包括高压或有毒的一氧化碳(Chem.Heterocycl.Compd.2009,45,757)、或有时几乎不可获得的N-(o-酮芳基)酰胺(N-(o-ketoaryl)amide),这形成了合成喹诺酮的限制因素/瓶颈。由于喹诺酮及其衍生物的重要性,一些研究小组对一锅法合成喹诺酮产生了兴趣。几种获得喹诺酮的多组分方法包括:铜催化取代的3-(2-卤代苯基)-3-氧代丙烷、醛和aq.NH3的三组分合成,其中,使用水作为溶剂介质(Adv.Synth.Catal.2019,361,1-15);用酰胺将炔酮氨酰化以得到取代的-3-芳酰基喹啉-4(1H)-酮骨架(Org.Lett.2010,12,212,J.Org.Chem.2016,81,12181,Org.Lett.2018,20,3907);用炔烃或烯烃邻位官能化苯胺以及氮杂-迈克尔加成替代法(J.Org.Chem.2015,80,1464,J.Org.Chem.2018,83,2694);在钯催化剂的存在下,邻碘苯胺与末端乙炔和一氧化碳的羰基化偶联(Tetrahedron Lett.1991,32,237),等等。鉴于喹诺酮的广泛应用,非常期望开发克服普遍挑战的新方法以及以一锅法为主来获得喹诺酮的环保策略。
发明目的
本发明的主要目的是提供新颖的式(I)的喹诺酮和类似物。
本发明的另一个目的是提供一种通过胺***法制备式(I)的喹诺酮和类似物的有效方法。
本发明的另一个目的是提供一种方法,该方法可以通过使用式(II)的预制炔酮(pre-installed ynone)在一锅法中使用添加剂和氨源的方案来进行。
本发明的另一个目的是天然产物例如芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)和假单素XII(6)的全合成。
本发明的另一个目的是扩展策略并以简洁的方法利用所获得的喹诺酮产物中的一种进行天然产物和他草喹诺酮F(7)的全合成。
发明内容
因此,本发明提供了一种式(I)的化合物:
其中,
X是C、N和C-OMe;
R1是H和CH3;
R2是C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基和3,4-亚甲基二氧苯基;
R3是H、Br和OMe;
R4是H、C1-C8烷基和溴;
R5和R6是H;以及
R5和R6能够结合在一起形成-OCH2O-。
在一个实施例中,本发明提供了一种通过胺***法制备通式(I)的喹诺酮的方法,包括具体实施方式中所述的步骤。
在优选的实施例中,本发明提供了一种式(2g)的化合物:
在一个实施例中,本发明提供了一种通式(II)的化合物:
其中,取代基R2、R4、R5、R6和X如上定义。
在另一个实施例中,本发明提供了一种制备通式(I)的喹诺酮的方法,包括:在金属卤化物作为添加剂的存在下,在极性溶剂如DMF或甲酰胺中,用氨源如碳酸铵、氨在约80-120℃下处理式(II)的炔酮约8-15小时。
在另一个实施例中,本发明提供了一种制备具有下式的芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)和假单素XII(6)的方法。
在另一个实施例中,本发明提供了一种制备式(7)的和他草喹诺酮F的方法,包括通式(I)的喹诺酮作为中间体。
在另一个实施例中,本发明提供了一种制备式(7)的和他草喹诺酮F的方法,包括以下步骤:
具体实施方式
本发明提供了制备喹诺酮及其衍生物的新颖且高效的方法及制备喹诺酮及其衍生物的中间体。
本发明的策略被扩展为利用所获得的喹诺酮产物中的一种进行天然产物的全合成,天然产物包括例如但不限于:芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)、假单素XII(6)和和他草喹诺酮F(7)。
如本文所用,修饰语“约”应该被认为是公开了由两个端点的绝对值限定的范围。例如,表述“约1至约4”还公开了“1至4”的范围。当用于修饰单个数字时,术语“约”可以指包括所指示数字在内的所述数字的±10%。例如,“约10%”可以覆盖9%到11%的范围,“约1”是指0.9到1.1。
在一个实施例中,本发明提供了以下式(I)的化合物:
其中,
X是C、N和C-OMe;
R1是H和CH3;
R2是C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基和3,4-亚甲基二氧苯基;
R3是H、Br和OMe;
R4是H、C1-C8烷基和溴;
R5和R6是H;以及
R5和R6能够结合在一起形成-OCH2O-。
在另一个实施例中,式(I)的化合物选自:
在最优选的实施例中,式(I)的化合物是:
在一个实施例中,本发明提供了由式(I)的化合物2k得到的化合物芸香宁碱(2):
在一个实施例中,本发明提供了通过胺***法制备通式(I)的喹诺酮的方法。
本方法可以通过使用预制炔酮在一锅法中使用添加剂和氨源的方案以高产率和高纯度来进行。该新开发的方法从预制炔酮(式I)开始,如图式1所示。
图式1:由式II合成式I
其中,
X是C、N和C-OMe;
R1是H和CH3;
R2是C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基和3,4-亚甲基二氧苯基;
R3是H、Br和OMe;
R4是H、C1-C8烷基和溴;
R5和R6是H;以及
R5-R6是-OCH2O-。
该方法可以非常有效地用多种底物(substrate)进行,并且是最适合于工业规模生产喹诺酮和类似物的高度可行策略。此外,该方法最适合于生成多种包含喹诺酮部分的中间体和相关分子。所有的反应/实验都包括单个反应产物的纯化和***表征,如在一般方法中所示。
制备喹诺酮和类似物、特别是通过如图式1所示的胺***法制备喹诺酮和类似物的该方法是包括使用添加剂和氨源以及其他反应参数的方案的最方便和简单的方法。
具体地,将式(II)的溴芳基炔酮化合物与无机碱如K2CO3或Cs2CO3或Na2CO3在极性溶剂如DMF或甲酰胺或DMSO或二恶烷中反应,并在碘化亚铜(I)的存在下加热该混合物以及乙酸铵或碳酸铵,得到式(I)的喹诺酮。
在一个优选的实施例中,本发明提供了制备通式(I)的喹诺酮的方法,包括:在金属卤化物作为添加剂的存在下,在极性溶剂如DMF或甲酰胺中,用氨源如碳酸铵、氨在约80-120℃下处理式(II)的炔酮约8-15小时。
在一个实施例中,本发明提供了制备通式(I)的喹诺酮的方法,其中,作为添加剂的金属卤化物选自碘化铜、溴化铜和氯化铜。
在一个实施例中,本发明提供了通式(II)的化合物:
其中,取代基R2、R4、R5、R6和X如上定义。
在另一个实施例中,式(II)的化合物选自:
在最优选的实施例中,式(II)的化合物是:
在另一个实施例中,本发明提供了制备具有通式(I)的芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)和假单素XII(6)的方法。
在另一个实施例中,本发明提供了制备通式(I)的芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)和假单素XII(6)的方法,包括:在金属卤化物作为添加剂的存在下,在极性溶剂如DMF或甲酰胺中用氨源如碳酸铵、氨处理式(II)的炔酮。
在一个实施例中,本发明提供了制备通式(I)的芸香碱(1)、芸香宁碱(2)、假单素IV(3)、假单素VII(4)、假单素VIII(5)和假单素XII(6)的方法,其中,作为添加剂的金属卤化物选自碘化铜、溴化铜和氯化铜。
在另一个实施例中,本发明提供了将通式(I)的喹诺酮作为中间体制备式(7)的和他草喹诺酮F的方法。
在另一个实施例中,本发明提供了制备式(7)的和他草喹诺酮F的方法,包括以下步骤。
在另一个实施例中,本发明具体地提供了制备8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮(2o)的方法;以及其作为全合成和他草喹诺酮F(7)的中间体的用途。
在另一个实施例中,本发明提供了制备和他草喹诺酮F(7)的方法,包括以下步骤:将8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮(2o)进行溴化,得到相应的溴化产物(8);在碘化铜的存在下,用甲醇钠处理溴化产物(8)得到和他草喹诺酮F(7)。
缩写列表
HPLC=高压液相色谱
TLC=薄层色谱
NMR=核磁共振
UV=紫外
HRMS=高分辨率质谱
GC=气相色谱
IR=红外光谱
DCM=二氯甲烷
THF:四氢呋喃
DCM:二氯甲烷
实验中使用的材料和方法
在该方法中使用的试剂和化学品购自AVRA或Spectrochem或Sigma-Aldrich,并且无需任何进一步纯化而直接使用。在该方法中,用试剂级溶剂进行后处理和纯化步骤。所有的反应/实验步骤都通过薄层色谱法进行监控,并且使用结晶或色谱法或蒸馏或萃取或过滤对获得的粗产物进行纯化,以便以良好产率获得纯化合物。此外,使用各种分析和光谱方法***地表征所有获得的化合物/产物。
测量方法
高分辨率质谱(HRMS)由Xero-G2-XS-QTOF HRMS仪和Thermo Fisher ScientificExactive(APCI)仪获得。在CDCl3或DMSO-d6溶剂中,在Bruker 600或500或400或300MHz上记录核磁共振(NMR)谱。1H NMR的化学位移以相对于四甲基硅烷(δ0.00ppm)的百万分之一(ppm)表示。13C NMR的化学位移以相对于CDCl3(δ77.0ppm)的ppm表示。数据报告如下:化学位移、多重性(s=单峰、d=二重峰、dd=双二重峰、t=三重峰、q=四重峰、quin=五重峰、sext=六重峰、m=多重峰)、耦合常数(Hz)和积分。
示例
以下示例通过说明的方式给出并且因此不应被解释为限制本发明的范围。
示例1:2-苯基喹啉-4(1H)-酮(2a)
示例2:2-(4-氟苯基)喹啉-4(1H)-酮(2b)
示例3:2-(4-乙基苯基)喹啉-4(1H)-酮(2c)
示例4:2-(4-甲氧基苯基)喹啉-4(1H)-酮(2d)
示例5:2-苯基-1,8-萘啶-4(1H)-酮(2e)
示例6:2-(2-氟苯基)喹啉-4(1H)-酮(2f)
示例7:5-溴-2-苯基喹啉-4(1H)-酮(2g)
示例8:6-苯基-[1,3]二氧杂环戊烯[4,5-g]喹啉-8(5H)-酮(2h)
示例9:6-(2-氟苯基)-[1,3]二氧杂环戊烯[4,5-g]喹啉-8(5H)-酮(2i)
示例10:2-(4-甲氧基苯基)-1,8-萘啶-4(1H)-酮(2j)
示例11:2-(苯并[d][1,3]二氧杂环戊烯-5-基)-1,8-萘啶-4(1H)-酮(2k)
示例12:2-环己基喹啉-4(1H)-酮(2l)
示例13:2-甲基喹啉-4(1H)-酮(2m)
示例14:2-环丙基喹啉-4(1H)-酮(2n)
示例15:8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮(2o)
示例16:2-(苯并[d][1,3]二氧杂环戊烯-5-基)-1-甲基喹啉-4(1H)-酮,芸香碱(1)
示例17:2-(苯并[d][1,3]二氧杂环戊烯-5-基)-4-甲氧基喹啉,芸香宁碱(2)
示例18:2-丁基喹啉-4(1H)-酮,假单素IV(3)
示例19:2-庚基喹啉-4(1H)-酮,假单素VII(4)
示例20:2-辛基喹啉-4(1H)-酮,假单素VIII(5)
示例21:2-十二烷基喹啉-4(1H)-酮,假单素XII(6)
如图式1所示的制备式I的化合物(2a-2o)的程序
图式1:由式II合成式I
其中,
X是C、N和C-OMe;
R1是H和CH3;
R2是C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基和3,4-亚甲基二氧苯基;
R3是H、Br和OMe;
R4是H、C1-C8烷基和溴;
R5和R6是H;以及
R5-R6是-OCH2O-。
一般程序1:在室温下,向Ace压力管(Sigma)中的式II的炔酮(0.2mmol)在非质子极性溶剂如甲酰胺、N,N,二甲基甲酰胺(1.5mL)中的搅拌溶液中加入氨源如氨或碳酸铵(1.0mmol)和金属卤化物如碘化铜(0.02mmol),紧闭盖子,将反应混合物在预热的油浴中于100℃加热12小时。之后,将反应混合物冷却至室温,用EtOAc(5mL)和冷水(5mL)稀释,分层并用EtOAc(5mL×2)萃取水层。将混合的有机萃取物用盐水溶液(5mL)洗涤,用Na2SO4干燥,减压除去挥发物,通过硅胶柱色谱法纯化获得的粗化合物,得到喹诺酮(2a-2q)和(3,4,5,6)。
示例1:2-苯基喹啉-4(1H)-酮(2a)
在室温下,向Ace压力管(Sigma)中的炔酮1a(57.0mg,0.2mmol)在甲酰胺(1.5mL)中的搅拌溶液中加入碳酸铵(97mg,1.0mmol)和碘化铜(4.0mg,0.02mmol),紧闭盖子,将反应混合物在预热的油浴中于100℃加热12小时。之后,将反应混合物冷却至室温,用EtOAc(5mL)和冷水(5mL)稀释,分层并用EtOAc(5mL×2)萃取水层。将混合的有机萃取物用盐水溶液(5mL)洗涤,用Na2SO4干燥,减压除去挥发物,通过硅胶柱色谱法纯化获得的粗化合物,得到浅棕色固体的喹诺酮2a(35.4mg,80%)。其中,Rf=0.3(50%EtOAc+己烷);1H NMR(400MHz,DMSO-d6)δ11.72(s,1H),8.11(dd,J=8.1,1.3Hz,1H),7.87–7.81(m,2H),7.78(d,J=8.3Hz,1H),7.68(ddd,J=8.4,7.0,1.5Hz,1H),7.63–7.56(m,3H),7.35(t,J=7.4Hz,1H),6.34(s,1H);13C NMR(101MHz,DMSO-d6)δ177.43,150.48,141.01,134.71,132.28,130.93,129.49,127.90,125.36,125.21,123.74,119.21,107.83.IR(neat):υmax 3545,2922,1692,1627,1589,1502,HRMS(ESIMS):calcd.for C15H12NO[M+H]+:calcdm/z 222.0919;found:222.0912
按照上述示例1(2a)所述的程序和包括相应的式II的反应物、碘化铜和甲酰胺作为溶剂的一般程序,来合成式2b-2o的化合物。
示例16:2-(苯并[d][1,3]二氧杂环戊烯-5-基)-1-甲基喹啉-4(1H)-酮,芸香碱(1)
在0℃下,向2k(30mg,0.11mmol)在无水THF(2mL)中的搅拌溶液中加入NaH(9mg,0.22)和MeI(18L,0.33),并在室温下继续搅拌3小时,用饱和NH4Cl水溶液猝灭,用2mL H2O稀释,用EtOAc(5mL×3)萃取。将混合的有机萃取物用Na2SO4干燥,减压除去挥发物得到粗化合物,将粗化合物通过柱色谱法纯化,得到浅棕色固体的1(22.4mg,71%)。Rf=0.35(50%EtOAc+己烷);Mp:188-190℃;1H NMR(500MHz,CDCl3)δ8.48(dd,J=8.0,1.5Hz,1H),7.70(ddd,J=8.6,7.1,1.6Hz,1H),7.54(d,J=8.6Hz,1H),7.42(t,J=7.5Hz,1H),6.90(dt,J=8.0,4.7Hz,2H),6.86(d,J=1.5Hz,1H),6.28(s,1H),6.06(s,2H),3.63(s,3H);13C NMR(126MHz,CDCl3)δ162.80,158.17,149.10,148.77,148.30,134.86,130.00,129.06,125.24,121.69,121.63,120.30,108.42,108.06,101.40,97.59,55.66;IR(neat):υmax2854,2100,1622,1541,1434,1201,1108,1023,784;HRMS(ESIMS):calcd.for C17H14NO3[M+H]+:calcd m/z 280.0974;found:280.0980。
示例17:2-(苯并[d][1,3]二氧杂环戊烯-5-基)-4-甲氧基喹啉,芸香宁碱(2)
室温下,向2k(30mg,0.11mmol)在无水DMF(2mL)中的搅拌溶液中加入K2CO3(30mg,0.22mmol)和MeI(18L,0.33mmol),在80℃下继续搅拌30分钟,用饱和NH4Cl水溶液猝灭,用2mL H2O稀释,用EtOAc(5mL×3)萃取。将混合的有机萃取物用Na2SO4干燥,减压除去挥发物得到粗化合物,将粗化合物通过柱色谱法纯化,得到浅棕色固体2(21.5mg,68%)。Rf=0.5(50% EtOAc+己烷);Mp:115-117℃;1H NMR(400MHz,DMSO)δ11.54(s,1H),8.08(dd,J=8.0,1.4Hz,1H),7.75(d,J=8.1Hz,1H),7.66(ddd,J=8.4,6.9,1.5Hz,1H),7.43(d,J=1.8Hz,1H),7.38(dd,J=8.1,1.9Hz,1H),7.35–7.29(m,1H),7.13(d,J=8.1Hz,1H),6.30(d,J=1.8Hz,1H),6.16(s,2H),3.32(s,3H);13C NMR(101MHz,CDCl3)δ162.81,158.15,149.06,148.77,148.30,134.80,130.01,129.02,125.24,121.70,121.62,120.30,108.42,108.05,101.39,97.58,55.66;IR(neat):υmax 2776,1728,1597,1498,1409,1239,1045,815;HRMS(ESIMS):calcd.for C17H14NO3[M+H]+:calcd m/z 280.0974;found:280.0975。
示例18:2-丁基喹啉-4(1H)-酮,假单素IV(3)
按照一般程序1,用炔酮1n,制备淡棕色固体的假单素IV(3)(31.7mg,79%)。
示例19:2-庚基喹啉-4(1H)-酮,假单素VII(4)
按照一般程序1,用炔酮1o,制备浅棕色固体的假单素VII(4)(39.8mg,82%);Rf=0.4(50% EtOAc+己烷)。
示例20:2-辛基喹啉-4(1H)-酮,假单素VIII(5)
按照一般程序1,用炔酮1p,制备浅棕色固体的假单素VIII(5)(39.0mg,76%);Rf=0.4(50% EtOAc+己烷)。
示例21:2-十二烷基喹啉-4(1H)-酮,假单素XII(6)
按照一般程序1,用炔酮1q,制备浅棕色固体的假单素XII(6)(48.8mg,78%);Rf=0.4(50% EtOAc+己烷)。
本发明还提供了由上面获得的产物之一(2o)来全合成和他草喹诺酮F(7)的简明方法,描述如下:
向8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮(2o)(100mg,0.31mmol)在乙腈(8mL)中的搅拌溶液中加入N-溴代丁二酰亚胺(60mg,0.35mmol)的乙腈(5mL)溶液,并在室温下继续搅拌。搅拌2小时后,用CH2Cl2(20mL)稀释反应混合物,用水(2×10mL)洗涤,用二氯甲烷(10mL)萃取水层,用Na2SO4干燥并减压浓缩,得到3-溴-8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮,其为浅棕色固体(79mg,70%)。将溶于DMF(5mL)中的3-溴-8-甲氧基-2-甲基-5-辛基喹啉-4(1H)-酮(79g,0.22mmol)、NaOMe(0.20mL,1.08mmol)和CuI(20mg,0.11mmol)置于50mL圆底烧瓶中。将混合物加热至120℃,然后搅拌2小时。反应完成后,将反应混合物通过硅藻土过滤并将滤液减压浓缩,得到黄色固体。通过硅胶柱色谱法(0-7%甲醇的二氯甲烷溶液)纯化产物,得到浅黄色固体的和他草喹诺酮F(7)(47mg,62%)。其中,M.p.110-112℃;1H NMR(500MHz,MeOD4)δ7.02(d,J=8.1Hz,1H),6.93(d,J=8.1Hz,1H),4.00(s,3H),3.77(s,3H),3.28–3.23(m,2H),2.48(s,3H),1.59(dt,J=15.2,7.4Hz,2H),1.42–1.35(m,2H),1.34–1.22(m,10H),0.88(t,J=7.0Hz,3H);13C NMR(101MHz,MeOD4)δ175.93,147.86,143.21,142.79,136.73,132.40,125.38,125.02,110.57,60.23,56.54,36.35,33.72,33.08,30.90,30.80,30.56,23.75,14.44,14.11;IR(neat):υmax 2920,1715,1621,1570,1521,1241,1182,1021,810,668;HRMS(ESIMS):calcd.for C20H30NO3[M+H]+:calcd m/z332.226;found:332.226。
式II的2-溴芳基-炔酮的制备
其中,X=C、N、C-OMe;R1=H、CH3;R2=C1-C12烷基、环丙基、环己基、苯基、2-氟苯基、4-氟苯基、4-甲氧基苯基、4-乙基苯基、3,4-亚甲基二氧苯基;R4=H、C1-C8烷基、溴;R5=H;R6=H;R5-R6=-OCH2O-。
一般程序2:用于合成代表性喹诺酮的式II的2-溴芳基炔酮(1a-1s)的制备
在-25℃至-15℃下,将碱如LiHMDS或n-BuLi(1.6M,5mmol)加入到搅拌的炔烃(6mmol)的无水THF(30mL)溶液中,并在同样的温度下将所得反应混合物再搅拌15分钟至半小时。向其中逐滴滴加2-溴芳基醛(5mmol)的THF(5mL)溶液,使其升温至室温,用TLC监测反应。在起始材料完全消耗后(通过TLC监测),通过逐滴滴加饱和NH4Cl水溶液(10mL)来淬灭反应混合物,并用H2O(40mL)和EtOAc(20mL)稀释。分层并用EtOAc(3×10mL)萃取水层。用盐水溶液洗涤混合的有机层,用无水Na2SO4干燥,减压浓缩得到粗产物,将粗产物通过柱色谱法(EtOAc/己烷,1:5)纯化得到炔丙醇。在室温下,向炔丙醇(10mmol)在DMSO(20mL)中的搅拌溶液中加入IBX(12mmol),并将反应混合物搅拌2-3小时。在起始材料完全消耗后(通过TLC监测),将反应混合物借助于EtOAc通过硅藻土过滤,所得滤液用冷H2O(25mL×2)、EtOAc(30mL)和盐水溶液(10mL)洗涤,并将有机层用无水Na2SO4干燥。减压除去挥发物,获得的粗混合物通过硅胶柱色谱法(EtOAc/己烷1:5)纯化,得到溴化取代的炔酮。
按照一般程序2和相应的具体起始材料,制备了下列化合物。
示例33:1-(2-溴苯基)丁基-2-炔-1-酮(1l):在0℃下,向2-溴苯甲醛(925mg,5.0mmol)在10mL THF的搅拌溶液中加入1-丙炔基溴化镁(12.0mL,0.5M在THF中,6.0mmol),搅拌1小时,用饱和NH4Cl水溶液(5mL)猝灭并用水(25mL)稀释,用EtOAc(2×25mL)萃取有机层,混合的有机萃取物用Na2SO4干燥并减压浓缩,得到粗仲醇,其用于下一步反应而无需进一步纯化。在室温下,向炔丙醇(5.0mmol)的DMSO(15mL)搅拌溶液中加入IBX(1.68g,6.0mmol),并将反应混合物搅拌2小时。将反应混合物借助于EtOAc(25mL)通过硅藻土过滤,所得滤液用冷H2O(25mL×2)洗涤。用EtOAc(25mL)萃取水层,混合的有机萃取物用盐水溶液(25mL)洗涤,用无水Na2SO4干燥。减压除去挥发物,所得粗混合物通过硅胶柱色谱(EtOAc/己烷1:5)纯化,得到无色液体的溴-炔酮(1l)(870mg,78%)。
示例40:1-(2-溴-3-甲氧基-6-辛基苯基)丁基-2-炔-1-酮(1s)
将双颈圆底烧瓶在高真空下脱气,在N2下将二异丙胺(0.64mL,4.52mmol)加入到无水THF(10.0mL)中,在-78℃下将n-BuLi(2.8mL,1.6M在THF中,4.52mmol)逐滴滴加到搅拌溶液中。搅拌30分钟后,将溶于10mL THF中的2,4-二溴-1-甲氧基苯(1.0g,3.77mmol)和DMF(0.21mL,2.65mmol)加入到黄色悬浮液中,反应混合物在室温下再搅拌15分钟,然后用饱和氯化铵溶液(10mL)淬灭。用水(25mL)稀释反应混合物,用EtOAc(2×25mL)萃取有机层,混合的有机萃取物用Na2SO4干燥并减压浓缩,得到粗化合物,将粗化合物通过硅胶柱色谱法纯化,得到浅黄色固体的二溴醛(800mg,73%)。其中,Mp:120-122℃;1H NMR(500MHz,CDCl3)δ10.29(s,1H),7.73(d,J=9.0Hz,1H),6.88(d,J=9.0Hz,1H),3.91(s,4H);13C NMR(126MHz,CDCl3)δ190.20,160.13,137.69,126.52,126.29,118.14,112.49,56.50;IR(neat):υmax2886,1692,1574,1456,1380,1267,1184,1128,1033,814,767;HRMS(ESIMS):calcd.forC8H7O2Br2[M+H]+:calcd m/z 292.8813;found:292.8828。在将Ace压力管脱气后,在管中装入2,6-二溴-3-甲氧基苯甲醛(750mg,2.56mmol)、正辛基硼酸(485mg,3.07mmol),依次加入Pd(PPH3)4(148mg,0.13mmol)、K2CO3(530mg,3.84mmol)和无水甲苯(12mL)。仔细密封该管,将反应混合物在100℃的油浴中加热12小时。冷却至室温后,将反应混合物通过硅藻土过滤并减压浓缩滤液,得到粗化合物,将粗化合物通过柱色谱法纯化,得到无色液体的偶联产物(544mg,65%)。其中,1H NMR(500MHz,CDCl3)δ10.52(s,1H),7.65(d,J=8.9Hz,1H),6.73(d,J=8.9Hz,1H),3.88(s,3H),3.05(dd,J=9.2,6.6Hz,2H),1.54–1.20(m,12H),0.88(t,J=7.0Hz,3H);13C NMR(126MHz,CDCl3)δ191.56,162.13,145.14,138.20,124.80,117.75,110.64,56.03,32.76,31.94,29.96,29.86,29.35,29.33,22.73,14.16;IR(neat):υmax2927,2857,1690,1575,1460,1408,1270,1173,1100,811,768;HRMS:(ESIMS):calcd.forC16H24O2Br[M+H]+:calcd m/z 327.0960;found:327.0969。
在0℃下,向辛基-溴-醛(530mg,1.62mmol)在10mL THF中的搅拌溶液中加入1-丙炔基溴化镁(3.9mL,0.5M在THF中,1.95mmol),搅拌1小时,用饱和NH4Cl水溶液(5mL)猝灭。用水(25mL)稀释,用EtOAc(2×25mL)萃取有机层,混合的有机萃取物用Na2SO4干燥并减压浓缩,得到粗仲醇,其无需进一步纯化即可用于下一步反应。在室温下,向搅拌着的炔丙醇(595mg,1.62mmol)在DMSO(10mL)中的溶液中加入IBX(545mg,1.95mmol),并将反应混合物搅拌2小时。借助于EtOAc(25mL),将反应混合物通过硅藻土过滤,所得滤液用冷H2O(25mL×2)洗涤。用EtOAc(25mL)萃取水层,混合的有机萃取物用盐水溶液(25mL)洗涤,用无水Na2SO4干燥。减压除去挥发物,所得粗混合物通过硅胶柱色谱法(EtOAc/己烷1:5)纯化,得到无色液体的溴-炔酮(1s)(473mg,80%)。其中,1H NMR(500MHz,CDCl3)δ7.49(d,J=8.8Hz,1H),6.66(d,J=8.8Hz,1H),3.81(s,3H),2.71–2.61(m,2H),2.05(s,3H),1.60–1.51(m,1H),1.40–1.21(m,11H),0.88(t,J=7.0Hz,3H);13C NMR(126MHz,CDCl3)δ181.10,155.84,139.90,134.34,131.57,116.04,110.59,92.80,81.71,56.13,33.34,31.89,29.85,29.26,22.71,14.15,4.54;IR(neat):υmax2926,2857,2225,1659,1575,1461,1274,1091,923,809,765;HRMS(ESIMS):calcd.for C19H26O2Br[M+H]+:calcd m/z 365.116;found:365.1135。
所开展工作的意义
鉴于喹诺酮的重要性,提出了一种在CuI存在下由2-溴芳基-炔酮和作为氨源的碳酸铵制备喹诺酮的新颖且高效的方法。炔酮可以从容易获得的商业材料中用两步骤方法容易地获得。由我们提出的本发明的合成式I的取代喹诺酮的方法是合成几种喹诺酮的非常有效的新方法,也是分别合成其天然产物假单素IV、VII、VIII、XII和和他草喹诺酮F的方法。
本发明的优点
下面给出了本发明的方法的各种优点。
1.本发明的方法是制备喹诺酮和类似物,特别是通过胺***法制备喹诺酮和类似物的高效和可放大生产的方法。
2.本发明的优点是所述方法可以通过使用氨源和添加剂一锅法操作。
3.本发明的另一个优点是包括非常可行的反应参数。
4.产物的分离和/或纯化是直接的。
5.这是生产喹诺酮和类似物,特别是喹诺酮的有吸引力和经济的方法。
6.所述方法可用于生产大量的过程中间体和喹诺酮类似物。
7.所述方法可以直接合成芸香碱。
8.所述方法可以直接合成芸香宁碱。
9.所述方法可以直接合成假单素IV。
10.所述方法可以直接合成假单素VII。
11.所述方法可以直接合成假单素VIII。
12.所述方法可以直接合成假单素XII。
13.所述方法的另一个优点包括利用开发的方法合成的喹烯酮用于天然产物和他草喹诺酮F的合成。
Claims (11)
5.如权利要求1所述的方法,包括:
将式(II)的溴芳基炔酮与无机碱在极性溶剂中反应,并且
在添加剂的存在下,将所述混合物与氨源在80-120℃加热8-15小时,得到式(I)的喹诺酮。
6.如权利要求5所述的方法,其中,
所述无机碱选自由碳酸铯、DBU、碳酸钾、碳酸钠、碳酸氢钾、碳酸氢钠、磷酸钾和碳酸铵组成的组,
所述极性溶剂选自由醚、醇、酯、二甲基甲酰胺、甲酰胺、二甲基亚砜和乙腈组成的组。
7.如权利要求5所述的方法,其中,
所述氨源选自氯化铵、醋酸铵、碳酸铵和甲酸铵,
所述添加剂选自碘化铜、溴化铜、氯化铜和醋酸铜。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202011036288 | 2020-08-22 | ||
IN202011036288 | 2020-08-22 | ||
PCT/IN2021/050790 WO2022044033A1 (en) | 2020-08-22 | 2021-08-17 | Quinolone compounds and process for preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115968368A true CN115968368A (zh) | 2023-04-14 |
Family
ID=80354810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180050996.5A Pending CN115968368A (zh) | 2020-08-22 | 2021-08-17 | 喹诺酮化合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240002348A1 (zh) |
EP (1) | EP4204410A1 (zh) |
JP (1) | JP2023538572A (zh) |
CN (1) | CN115968368A (zh) |
WO (1) | WO2022044033A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205778A1 (en) * | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101766414B1 (ko) * | 2016-04-07 | 2017-08-08 | 덕성여자대학교 산학협력단 | 1-알킬-2-페닐-1,8-나프티리딘-4-온의 신규한 제조방법 |
WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
-
2021
- 2021-08-17 WO PCT/IN2021/050790 patent/WO2022044033A1/en unknown
- 2021-08-17 US US18/042,570 patent/US20240002348A1/en active Pending
- 2021-08-17 JP JP2023511971A patent/JP2023538572A/ja active Pending
- 2021-08-17 EP EP21860771.1A patent/EP4204410A1/en active Pending
- 2021-08-17 CN CN202180050996.5A patent/CN115968368A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101766414B1 (ko) * | 2016-04-07 | 2017-08-08 | 덕성여자대학교 산학협력단 | 1-알킬-2-페닐-1,8-나프티리딘-4-온의 신규한 제조방법 |
WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
Non-Patent Citations (4)
Title |
---|
JUN SHAO等: "sSpeycinal ttohpiecsis of N-Alkyl-Substituted 4-Quinolones via Tandem Alkenyl and Aryl C–N Bond Formation", SYNTHESIS, vol. 44, 4 March 2012 (2012-03-04), pages 1798 * |
SHWETA SINGH等: "Access to 2‑Alkyl/Aryl-4-(1H)‑Quinolones via Orthogonal "NH3" Insertion into o‑Haloaryl Ynones: Total Synthesis of Bioactive Pseudanes, Graveoline, Graveolinine and Waltherione F", ORGANIC LETTERS, vol. 22, no. 4, 4 February 2020 (2020-02-04), pages 1575 - 1579 * |
SREENIVASULA REDDY BANDATMAKURU等: "Novel synthesis of graveoline and graveolinine", SYNTHETIC COMMUNICATIONS, vol. 48, no. 20, 22 October 2018 (2018-10-22), pages 2635 - 2641, XP055909364, DOI: 10.1080/00397911.2018.1501581 * |
VICTOR ZDORICHENKO等: "The Synthesis of Waltherione F and Its Analogues with Modifications at the 2- and 3-Positions as Potential Antitrypanosomal Agents", CHEM. EUR. J., vol. 25, 31 December 2019 (2019-12-31), pages 1286 - 1292, XP055909371, DOI: 10.1002/chem.201804061 * |
Also Published As
Publication number | Publication date |
---|---|
US20240002348A1 (en) | 2024-01-04 |
WO2022044033A1 (en) | 2022-03-03 |
JP2023538572A (ja) | 2023-09-08 |
EP4204410A1 (en) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kiyani et al. | Potassium phthalimide as efficient basic organocatalyst for the synthesis of 3, 4-disubstituted isoxazol-5 (4H)-ones in aqueous medium | |
US5932732A (en) | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | |
TW201609694A (zh) | 用於製備3-(3-氯-1h-吡唑-1-基)吡啶的方法(一) | |
CN113423690B (zh) | 吡唑衍生物 | |
JP2013056912A (ja) | 2−置換−5−(1−アルキルチオ)アルキルピリミジンの製造方法 | |
Pathak et al. | Trifluoroacetic acid: a more effective and efficient reagent for the synthesis of 3-arylmethylene-3, 4-dihydro-1H-quinolin-2-ones and 3-arylmethyl-2-amino-quinolines from Baylis–Hillman derivatives via Claisen rearrangement | |
CN115968368A (zh) | 喹诺酮化合物及其制备方法 | |
Jiang et al. | Mg (ClO4) 2-catalyzed intramolecular allylic amination: application to the total synthesis of demethoxyfumitremorgin C | |
Liu et al. | Concise asymmetric synthesis of (−)-deoxoprosophylline | |
JP5077969B2 (ja) | 2−置換5−(1−アルキルチオ)アルキルピリジンの調製方法 | |
JP7205529B2 (ja) | オキサゾリジノン化合物の製造方法 | |
Zhang et al. | Copper (I)‐Catalyzed Intramolecular N‐N Coupling of Cyclopropyl O‐Acyl Ketoximes: Synthesis of Spiro‐fused Pyrazolin‐5‐ones | |
CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
Padwa et al. | An efficient synthesis of furyl sulfonamides from the reaction of furan with in situ generated N-tosyl imines | |
JP7205059B2 (ja) | エボジアミンの製造方法 | |
Pierry et al. | Diastereocontrolled addition of organometallic reagents to S-chiral N-(tert-butanesulfinyl)-α-fluoroenimines | |
Wei et al. | Palladium (0)-catalyzed 5-exo-dig O-cyclization/coupling of ethyl 3-(2-alkynylphenyl)-3-oxopropanoates with aryl iodides to 1, 3-dihydroisobenzofurans | |
CN114790212B (zh) | 恶嗪并异吲哚和恶嗪并异喹啉化合物及其制备方法 | |
CN105837579A (zh) | 一种多取代苯并[4,5]咪唑并[1,2-b]吡唑衍生物的制备方法 | |
JP6006634B2 (ja) | イソウレア化合物を用いるエピナスチンの製造方法 | |
WO2020213714A1 (ja) | シス-(-)-フロシノピペリドールの製造方法 | |
Reboredo et al. | Highly diastereoselective C→ N acyl rearrangement in polysubstituted pyrrolidine 2, 2-dicarboxylates. Stereocontrolled synthesis of densely functionalized prolines | |
Yoshida et al. | Enantioselective synthesis of a chiral pyridazinone derivative by lipase-catalyzed hydrolysis | |
WO2012157504A1 (ja) | β-ラクタム化合物およびその製造方法 | |
CN115353514B (zh) | 氟代吡啶并嘧啶酮类化合物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |